May maybes as Spanish in prepares to pay back d€bt €Billions to pharma
This article was originally published in Scrip
There is soon to be some relief for pharmaceutical companies in Spain that have been struggling to recover hospital debts related to drug purchases totalling €6.3 billion. A €35 billion "liquidity injection" from the central Spanish government should see regional and local authorities start to pay back providers, said the treasury this week. However, it is far from clear that the financial jab in the arm provides any comfort for the pharma industry beyond the immediate future.
You may also be interested in...
Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.
Softening provisions to make EU-wide joint clinical assessments voluntary would make proposed legislation on HTA cooperation redundant, says Eurordis.